The effects of abaloparatide on acetabular bone mineral density and proximal femur strength in men with osteoporosis.

Deal C, Bostrom MP, Sheth NP, Humbert L, Krohn KD, Wang Y, Boxberger JI

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry17 Feb 2026

PMID41812602DOI10.1016/j.jocd.2026.101686PepBankPUB-41812602

Publisher page PubMedAsk about this study

Jump to 5 results

Summary

BackgroundAbaloparatide treatment for 12 months led to significant and rapid increases in bone mineral density (BMD) in the lumbar spine, total hip, and femoral neck compared with placebo in the phase 3 ATOM study (NCT03512262) in men with osteoporosis.MethodologyAcetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups. First, acetabular BMD was calculated in the DeLee and Charnley zones. Second, DXA scans were processed through 3D-Shaper software to generate three-dimensional (3D) patient-specific femur models and calculate femur strength based on a finite element analysis simulating sideways falls.Results and conclusionsAt 6 and 12 months, mean acetabular BMD significantly increased from baseline in all DeLee and Charnley zones with abaloparatide, while little change was noted with placebo. In the second analysis, mean percent change from baseline in femur strength was significantly increased in the abaloparatide treatment group at 6 and 12 months, largely attributable to significant strength increases in the trabecular bone of the femur. Femur and femoral trabecular strength remained near baseline levels in the placebo group. Femoral cortical strength numerically increased in the abaloparatide group at 12 months, though the change was not significant.^d The anatomical distribution of changes in major principal stress at failure at 6 and 12 months indicated that the stress at which failure occurs increased at the upper aspect of the femur neck in the abaloparatide group.^e In conclusion, abaloparatide improved measured properties in men with osteoporosis on acetabular and femoral sides of the hip joint, increasing acetabular BMD and improving femur strength parameters. Additional research into abaloparatide's role in managing bone loss at the hip is justified.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In men with osteoporosis, abaloparatide significantly increased acetabular BMD from baseline in all DeLee and Charnley zones at 6 and 12 months.
In plain wordsIn men with osteoporosis, abaloparatide increased hip socket bone density from baseline at 6 and 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseAcetabular BMD
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
At 6 and 12 months, mean acetabular BMD significantly increased from baseline in all DeLee and Charnley zones with abaloparatide, while little change was noted with placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Acetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups.
Show in the study text Report a problemFND-4181260201
02Computer modelIn silicoEfficacy outcome
In men with osteoporosis, abaloparatide significantly increased modeled femur strength from baseline at 6 and 12 months.
In plain wordsIn computer models, abaloparatide increased modeled thigh bone strength from baseline at 6 and 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemur strength
Study
n: not reported in source
DXA-derived finite element femur models
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
In the second analysis, mean percent change from baseline in femur strength was significantly increased in the abaloparatide treatment group at 6 and 12 months, largely attributable to significant strength increases in the trabecular bone of the femur.
2 context sentences(design, population, supporting numbers)
Summary · context
Acetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups.
Summary · context
Second, DXA scans were processed through 3D-Shaper software to generate three-dimensional (3D) patient-specific femur models and calculate femur strength based on a finite element analysis simulating sideways falls.
Show in the study text Report a problemFND-4181260202
03Computer modelIn silicoEfficacy outcome
In men with osteoporosis, abaloparatide significantly increased modeled femoral trabecular strength from baseline at 6 and 12 months.
In plain wordsIn computer models, abaloparatide increased modeled spongy thigh bone strength from baseline at 6 and 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral trabecular strength
Study
n: not reported in source
DXA-derived finite element femur models
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
In the second analysis, mean percent change from baseline in femur strength was significantly increased in the abaloparatide treatment group at 6 and 12 months, largely attributable to significant strength increases in the trabecular bone of the femur.
2 context sentences(design, population, supporting numbers)
Summary · context
Acetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups.
Summary · context
Second, DXA scans were processed through 3D-Shaper software to generate three-dimensional (3D) patient-specific femur models and calculate femur strength based on a finite element analysis simulating sideways falls.
Show in the study text Report a problemFND-4181260203
04Computer modelIn silicoEfficacy outcome
In men with osteoporosis, femoral cortical strength increased numerically with abaloparatide at 12 months, without statistical significance.
In plain wordsIn computer models, the modeled outer thigh bone strength increase with abaloparatide at 12 months was not significant.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeFemoral cortical strength
Study
n: not reported in source
DXA-derived finite element femur models
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
Femoral cortical strength numerically increased in the abaloparatide group at 12 months, though the change was not significant.
2 context sentences(design, population, supporting numbers)
Summary · context
Acetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups.
Summary · context
Second, DXA scans were processed through 3D-Shaper software to generate three-dimensional (3D) patient-specific femur models and calculate femur strength based on a finite element analysis simulating sideways falls.
Show in the study text Report a problemFND-4181260204
05Computer modelIn silicoEfficacy outcome
In men with osteoporosis, modeled failure stress increased at the upper femoral neck with abaloparatide at 6 and 12 months.
In plain wordsIn computer models, modeled upper thigh bone neck failure stress increased with abaloparatide at 6 and 12 months.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral neck stress at failure
Study
n: not reported in source
DXA-derived finite element femur models
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
The anatomical distribution of changes in major principal stress at failure at 6 and 12 months indicated that the stress at which failure occurs increased at the upper aspect of the femur neck in the abaloparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
Acetabular BMD and femur strength were analyzed in separate analyses using dual energy X-ray absorptiometry (DXA) scans from men in the abaloparatide and placebo groups.
Summary · context
Second, DXA scans were processed through 3D-Shaper software to generate three-dimensional (3D) patient-specific femur models and calculate femur strength based on a finite element analysis simulating sideways falls.
Show in the study text Report a problemFND-4181260205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03512262

Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)

Radius Health, Inc.n = 2283 May 2018 to 8 Sept 2021

Osteoporosis · Osteoporosis, Age-Related · Osteoporosis Localized to Spine · Age Related Osteoporosis · Osteoporosis Senile · Osteoporosis of Vertebrae

Trial page ClinicalTrials.govUpdated 7 Apr 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.